Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer

[1]  B. Glimelius.  Biochemical modulation of 5-fluorouracil: a randomized comparison of sequential methotrexate, 5-fluorouracil and leucovorin versus sequential 5-fluorouracil and leucovorin in patients with advanced symptomatic colorectal cancer. The Nordic Gastrointestinal Tumor Adjuvant Therapy Group. , 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  M. Borner,et al.  More is not always better: a case for low-dose leucovorin. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  R. Christopherson,et al.  Antifolates induce inhibition of amido phosphoribosyltransferase in leukemia cells. , 1992, The Journal of biological chemistry.

[4]  P. Piedbois.  Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  H. Wieand,et al.  Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  J. Carles,et al.  Sequential Combination of Methotrexate (MTX), 5‐Fluorouracil (FU), and High‐Dose Folinic Acid (FA) in Advanced Colorectal Cancer: Double Biochemical Modulation? , 1991, American journal of clinical oncology.

[7]  C. Vallejo,et al.  Advanced colorectal carcinoma. A prospective randomized trial of sequential methotrexate, 5-fluorouracil, and leucovorin versus 5-fluorouracil alone. , 1991, American journal of clinical oncology.

[8]  J. Bertino,et al.  The influence of drug interval on the effect of methotrexate and fluorouracil in the treatment of advanced colorectal cancer. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  J. Laurie,et al.  Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  J. Hannigan,et al.  Treatment of patients with advanced colorectal carcinomas with fluorouracil alone, high-dose leucovorin plus fluorouracil, or sequential methotrexate, fluorouracil, and leucovorin: a randomized trial of the Northern California Oncology Group. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  N. Petrelli,et al.  A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  B. Leone,et al.  Sequential therapy with methotrexate and 5-fluorouracil in the treatment of advanced colorectal carcinoma. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  J. Hannigan,et al.  Phase II study of sequential methotrexate and 5-FU plus mitomycin and leucovorin in patients with disseminated large bowel cancer: a Northern California Oncology Group study. , 1984, Cancer treatment reports.

[14]  R. Herrmann,et al.  Sequential methotrexate and 5-fluorouracil: improved response rate in metastatic colorectal cancer. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  N. Kemeny,et al.  Activity of sequential low-dose methotrexate and fluorouracil in advanced colorectal carcinoma: attempt at correlation with tissue and blood levels of phosphoribosylpyrophosphate. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  J. Bertino,et al.  Time and dose relationships for methotrexate (MTX), fluorouracil (FUra) and combinations of these drugs for maximum cell kill in human CCRF-CEM cells , 1982 .

[17]  C. Benz,et al.  The influence of methotrexate pretreatment on 5-fluorouracil metabolism in L1210 cells. , 1981, The Journal of biological chemistry.

[18]  M. Choti,et al.  Schedule-dependent cytotoxicity of methotrexate and 5-fluorouracil in human colon and breast tumor cell lines. , 1980, The Journal of clinical investigation.

[19]  K. Danenberg,et al.  Effect of 5, 10-methylenetetrahydrofolate on the dissociation of 5-fluoro-2'-deoxyuridylate from thymidylate synthetase: evidence for an ordered mechanism. , 1978, Biochemistry.

[20]  M. Pike,et al.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.

[21]  J. Bertino,et al.  Schedule-dependent antitumor effects of methotrexate and 5-fluorouracil. , 1977, Cancer research.

[22]  David R. Cox,et al.  Regression models and life tables (with discussion , 1972 .

[23]  D. Cox,et al.  The analysis of binary data , 1971 .

[24]  W. Haenszel,et al.  Statistical aspects of the analysis of data from retrospective studies of disease. , 1959, Journal of the National Cancer Institute.